This month, Nucleus Network welcomes Dr. Graham Wood as the new Executive Vice President, leading the Minneapolis clinic and Nucleus Network USA operations alongside our two Australian locations, Melbourne and Brisbane. His appointment comes after the planned retirement of current co-founder and leader of the company formerly known as Prism Research Jeff Cosgrove.
In Jeff’s 30 years of experience in the sector, he has worked in many roles, from recruitment management to operational management before founding Prism Research in 2004. Jeff’s in-depth understanding and experience across the clinical operations value chain has led to the successful execution of over 900 early phase research protocols since 1990. His understanding of the needs of the sector and ability to recruit and retain an excellent team of people around him helped make Prism an incredible success story.
Jeff has been involved in the selection and handover of the leadership of the site to Dr. Graham Wood, effective July 5th.
Dr. Wood is a leader in the conduct and design of clinical pharmacology studies, having held senior executive roles in a number of the top clinical research sites in the world.
In his 22 years of experience, he has been involved with more than 200 first-in-human studies as well as over 2,000 studies across all areas of clinical pharmacology.
After finishing his PhD in Neurology and Neurosurgery, Graham worked at MDS Pharma Services, Cetero Research, Manna Research and Altasciences as well as spending two years working at biotechnology companies. His most recent role was as the Chief Operating Officer at Tetra Bio-Pharma.
Graham joins Nucleus Network to continue to build the industry-leading capabilities of our Minneapolis facility in specialized renal and hepatic studies and healthy volunteer trials. Currently delivering approximately 100 early phase trials annually across our three locations, for our international client base including large Pharmaceutical and biotech companies, he will also support the overall growth of Nucleus Network and further expansion in the USA.
Graham’s experience and understanding of the clinical trials sector, along with the already high-performing team we have at our Minneapolis site will no doubt continue the tradition of success that began with Prism Research 15 years ago.
We wish Jeff all the best in retirement, and welcome Dr. Wood into the company. We look forward to working with him and our clients in advancing medicine, improving lives.